Team:Freiburg Bioware/Project/Project Description

From 2010.igem.org

(Difference between revisions)

Revision as of 18:39, 24 October 2010

The Experimental System

Therapy using viral vectors is an promising approach for.... In an first step the plasmids of the AAV-2 Helper-free System were genetically modifyed by converting it into BioBricks and inserting of targeting molecules into the constructs. These plasmids were then used to transfect the producer cell line AAV-293. After an incubation of three days the viral vectors were harvested and used to transduce different target cells. The succesful transduction can then for example be measured by detecting the fluorescence of fluorescent proteins in the target cells.

The majority of the modifications that were introduced into the viral vector aimed to allow differential targeting of tumor cell over healthy off-target cells.

Modularization of the rAAV genome

Text

Modulatization of the RepCap plasmid

Text

Modulatization of the Vectorplasmid

Text

Modification of the viral surface in one cloning step - The ViralBrick standard

Text

Midifications of the Virus Shell via Loop Insertions

Text

Specific biotinylation of the Viral Schell - The Biotinylation Acceptor Peptide (BAP)

Text

Purification of Therapeutic Viral Vectors - The His-Affinity Tag

Text

Targeting of integrin overexpressing cells - The RGD Motif

Text

Arming the Viral Vector with therapeutic antibodies - The Z34C Motif

Text

Testing the limit for loop insertion - The Beta-Lactamase

Text

Method Development

Text

Arming: Killing the Tumor

Text

All-In-One: Testing multiple modified Viral Vectors

Text

Virus Construction Kit - The Manual

Text

@@ Line 7: / Line 7: @@
 <div style="float:left; width:460px; height:auto;  margin: 0px 5px 0px 5px; text-align:justify;border: 1px solid black;"><p>
 Therapy using viral vectors is an promising approach for....
-In an first step the plasmids of the AAV-2 Helper-free System were genetically modifyed by converting it into BioBricks and inserting of targeting molecules into the constructs. These plasmids were then used to transfect the producer cell line AAV-293. After an incubation of three days the viral vectors were harvested and used to transduce different target cells. The succesful transduction can then for example be measured by detecting the fluorescence of fluorescent proteins in the target cells.
+In an first step the plasmids of the AAV-2 Helper-free System were genetically modifyed by converting it into BioBricks and inserting of targeting molecules into the constructs. These plasmids were then used to transfect the producer cell line AAV-293. After an incubation of three days the viral vectors were harvested and used to transduce different target cells. The succesful transduction can then for example be measured by detecting the fluorescence of fluorescent proteins in the target cells.<br><br>
+The majority of the modifications that were introduced into the viral vector aimed to allow differential targeting of tumor cell over healthy off-target cells.
 </p></div>
 <div style="float:right; width:420px; height:auto; "><img src="https://static.igem.org/mediawiki/2010/3/38/Freiburg10_Experimental_System.png" width="420"